Compare ProShares Ultra QQQ ETF (QLD) vs Viatris Inc (VTRS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
ProShares Ultra QQQ ETF vs Viatris Inc — how do they compare? ProShares Ultra QQQ ETF trades at $98.03 (market cap $15.38B), while Viatris Inc trades at $17.35 (market cap $20.03B). The key difference: Viatris Inc is the larger of the two by market cap, and Viatris Inc pays a 2.75% dividend while ProShares Ultra QQQ ETF pays none. Which is the better fit depends on your goals — on Pluang, investors hold ProShares Ultra QQQ ETF for 37 Days and Viatris Inc for 57 Days on average.
| QLD | VTRS | |
|---|---|---|
Market Cap | $15.38B | $20.03B |
Volume | 4,844,085 | 14,109,977 |
Sector | Leveraged / Inverse | Health |
52-Week High | $100.77 | $18.27 |
52-Week Low | $57.16 | $9.74 |
Typical Hold Time | 37 Days | 57 Days |
Enterprise Value | — | $32.15B |
Dividend Yield | — | 2.75% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
QLD trades at $100.23, down 0.54% on the day, with technical indicators showing a bullish moving average signal but overbought RSI conditions. The ETF maintains support at $99 and resistance at $101, with institutional buying activity noted in recent filings. Recent news highlights QLD's resilience compared to more leveraged alternatives during market downturns.
The outlook remains cautiously optimistic given strong technical momentum, though overbought conditions suggest potential near-term consolidation. Key risks include Federal Reserve policy impacts and Nasdaq volatility, while institutional accumulation supports medium-term bullish sentiment.
Viatris (VTRS) trades at $17.49, down 0.29% with a bullish technical signal supported by moving averages and oversold RSI levels. The company shows consistent earnings beats with Q2 2026 EPS of $0.69 exceeding expectations, while maintaining strong operational cash flow of $2.32B in 2025. Recent developments include FDA approval for WAKIX in Japan and continued recognition as a top employer.
Despite negative net margins, Viatris demonstrates improving cash flow trends and strategic portfolio optimization. The stock offers 27% upside to consensus price target of $22.17, though investors face risks from debt levels and competitive pressures in the generic drug market. Deleveraging progress and pipeline advancements support potential re-rating.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About ProShares Ultra QQQ ETF
QLD is a leveraged ETF that seeks daily investment results corresponding to 200% of the daily performance of the NASDAQ-100 Index. It achieves 2x leverage by investing in financial instruments such as swaps and is designed as a tactical trading tool for investors with a bullish (long) view on the NASDAQ-100. Due to the effects of compounding and leverage, the ETF is intended to be held for a single day and is not suitable for long-term investment.
Read more on QLD →About Viatris Inc
Formed by the combination of Mylan and Pfizer's Upjohn business in 2020, Viatris is one of the world's largest generic drug manufacturers, with a substantial off-patent branded drug portfolio. Its portfolio consists of more than 1,400 molecules with penetration across most of the developed world and in select emerging markets. The company's branded drug portfolio consists of off-patent blockbuster drugs that continue to generate strong sales, including Lipitor, Norvasc, Lyrica, Viagra, and EpiPen. While global competition has facilitated the commodification of small-molecule generic drugs, the company has demonstrated an edge over peers in its ability to manufacture complex generics (for example, generic Advair and Copaxone).
Read more on VTRS →
